- Powder
- Tablet
- Capsule
Cholinergic Drugs Market was valued at USD 8,637.2 million in 2023 and poised to grow at 9.1% CAGR from (2024-2030). Cholinergic drugs are medications that simulate or increase the activity of the neurotransmitter acetylcholine in the nervous system. These drugs act on cholinergic receptors, which can be broadly categorized as either muscarinic or nicotinic receptors. Cholinergic drugs are used in several medical conditions, including Alzheimer's disease, glaucoma, myasthenia gravis, and some gastrointestinal disorders. The growing incidence of neurological conditions such as Alzheimer's disease, Parkinson's disease, and myasthenia gravis drives the demand for cholinergic drugs. The prevalence rate of alzheimer's disease has increased within the past decades all over the world.
For Instance, the WHO estimates that over 55 million people worldwide live with dementia, with Alzheimer's disease being the most common cause. Moreover, an increasing number of elderly individuals leads to a higher prevalence of age-related diseases requiring cholinergic drug therapy. However, stringent regulatory requirements for the approval of new drugs can delay market entry and increase development costs and restrain the market growth. Whereas, developing combination therapies that include cholinergic drugs with other treatments can enhance therapeutic outcomes and market potential. Also, advances in genomics and personalized medicine can lead to the development of tailored cholinergic therapies, address specific patient needs.
Cholinergic Drugs Market Key Devlopments:
- In 2023, the drug which is a combination of xanomeline, a muscarinic receptor agonist, and trospium, a muscarinic receptor antagonist. It is used for the treatment of schizophrenia and works by targeting the cholinergic system
- In 2023, the U.S. Food and Drug Administration (FDA) approved a new formulation of donepezil, designed for extended-release delivery to improve patient compliance and reduce gastrointestinal side effects.
Cholinergic Drugs Market Summary
Study Period
2024-2030Base Year
2023CAGR
9.1%Largest Market
North AmericaFastest Growing Market
Asia PacificCholinergic Drugs Market Dynamics
Another major driver of the cholinergic drugs market is the increasing number of neurological disorders, of which Alzheimer's disease accounts for the highest percentage. AD is a neurodegenerative disorder characterized by a decline in cognitive function correlated with a cholinergic deficit in the brain. Cholinergic drugs, like donepezil, rivastigmine, and galantamine, work by increasing cholinergic activity and are under use to manage, at least slow down, the symptoms of AD.
The problem of Alzheimer's disease has been increasing over the last decades and become a public health concern globally. According to estimations by the WHO, in 2020, 50 million people were living with dementia of which the most common form is Alzheimer's disease and this number is projected to increase to 152 million by 2050. Such surging demands, therefore, require cholinergic therapy for the management of symptoms and improved quality of life among patients.
North-America Got Significant Share
Cholinergic Drugs Market Regional Analysis
Based on the region, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. North America, driven by the United States, dominates the cholinergic drugs market due to the high incidence of neurological disorders, superior health infrastructure, and heavy investments in the pharma R&D sector. The Alzheimer's Association reported that in 2021, an estimated 6.2 million Americans aged 65 and older were living with Alzheimer's dementia. This number is projected to increase to nearly 13 million by 2050.
However, Europe is another major market for cholinergic drugs, driven by an aging population, high prevalence of dementia, and robust healthcare systems. In the UK alone, over 850,000 people are living with dementia, with projections to rise significantly in the coming decades. Furthermore, the Asia-Pacific region is experiencing rapid growth in the cholinergic drugs market due to increasing healthcare expenditure, growing awareness of neurological disorders, and a large aging population.
Latin America
Europe
Asia Pacific
Middle East
North America
Cholinergic Drugs Market Segmentation
By Type
By Drug Type
- Muscarinic Agonists
- Nicotinic Agonists
- Acetylcholinesterase Inhibitors
By Induction
- Alzheimer's Disease
- Myasthenia Gravis
- Glaucoma
- Overactive Bladder
- Schizophrenia
By Application
- Hospital Pharmacy
- Retail Pharmacy
Geography
- North America
- Europe
- Asia pacific
- Latin America
- Middle east
Frequently Asked Questions
Cholinergic drugs are medications that mimic or enhance the action of acetylcholine in the nervous system, used to treat conditions like Alzheimer's disease, glaucoma, and myasthenia gravis.
The increasing prevalence of neurological disorders, an aging population, advancements in drug development, and rising awareness of eye and cognitive health drive demand.
North America leads the market due to a high prevalence of neurological disorders, advanced healthcare infrastructure, significant pharmaceutical investments, and supportive regulatory frameworks.
Challenges include potential side effects of cholinergic drugs, high treatment costs, stringent regulatory requirements, and competition from alternative therapies.
The market is expected to grow rapidly in emerging regions like Asia-Pacific due to increasing healthcare expenditures, rising awareness of neurological disorders, and expanding access to advanced medical treatments.
Key Features of the Report
- The cholinergic drugs market report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and key strategies.
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market.
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market.
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenarios.
| 1.Executive Summary |
| 2.Global Cholinergic Drugs Market Introduction |
| 2.1.Global Cholinergic Drugs Market - Taxonomy |
| 2.2.Global Cholinergic Drugs Market - Definitions |
| 2.2.1.Type |
| 2.2.2.Drug Type |
| 2.2.3.Induction |
| 2.2.4.Application |
| 2.2.5.Region |
| 3.Global Cholinergic Drugs Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Cholinergic Drugs Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Cholinergic Drugs Market By Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Powder |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Tablet |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Capsule |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 6.Global Cholinergic Drugs Market By Drug Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Muscarinic Agonists |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Nicotinic Agonists |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Acetylcholinesterase Inhibitors |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7.Global Cholinergic Drugs Market By Induction, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Alzheimer's Disease |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Myasthenia Gravis |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Glaucoma |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Overactive Bladder |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Schizophrenia |
| 7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8.Global Cholinergic Drugs Market By Application, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. Hospital Pharmacy |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Retail Pharmacy |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 9.Global Cholinergic Drugs Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. North America |
| 9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.1.3. Market Opportunity Analysis |
| 9.2. Europe |
| 9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.2.3. Market Opportunity Analysis |
| 9.3. Asia Pacific (APAC) |
| 9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.3.3. Market Opportunity Analysis |
| 9.4. Middle East and Africa (MEA) |
| 9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.4.3. Market Opportunity Analysis |
| 9.5. Latin America |
| 9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.5.3. Market Opportunity Analysis |
| 10.North America Cholinergic Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Powder |
| 10.1.2.Tablet |
| 10.1.3.Capsule |
| 10.2. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Muscarinic Agonists |
| 10.2.2.Nicotinic Agonists |
| 10.2.3.Acetylcholinesterase Inhibitors |
| 10.3. Induction Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Alzheimer's Disease |
| 10.3.2.Myasthenia Gravis |
| 10.3.3.Glaucoma |
| 10.3.4.Overactive Bladder |
| 10.3.5.Schizophrenia |
| 10.4. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Hospital Pharmacy |
| 10.4.2.Retail Pharmacy |
| 10.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.5.1.United States of America (USA) |
| 10.5.2.Canada |
| 11.Europe Cholinergic Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Powder |
| 11.1.2.Tablet |
| 11.1.3.Capsule |
| 11.2. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Muscarinic Agonists |
| 11.2.2.Nicotinic Agonists |
| 11.2.3.Acetylcholinesterase Inhibitors |
| 11.3. Induction Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Alzheimer's Disease |
| 11.3.2.Myasthenia Gravis |
| 11.3.3.Glaucoma |
| 11.3.4.Overactive Bladder |
| 11.3.5.Schizophrenia |
| 11.4. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.Hospital Pharmacy |
| 11.4.2.Retail Pharmacy |
| 11.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.5.1.Germany |
| 11.5.2.France |
| 11.5.3.Italy |
| 11.5.4.United Kingdom (UK) |
| 11.5.5.Spain |
| 12.Asia Pacific (APAC) Cholinergic Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Powder |
| 12.1.2.Tablet |
| 12.1.3.Capsule |
| 12.2. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Muscarinic Agonists |
| 12.2.2.Nicotinic Agonists |
| 12.2.3.Acetylcholinesterase Inhibitors |
| 12.3. Induction Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Alzheimer's Disease |
| 12.3.2.Myasthenia Gravis |
| 12.3.3.Glaucoma |
| 12.3.4.Overactive Bladder |
| 12.3.5.Schizophrenia |
| 12.4. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.Hospital Pharmacy |
| 12.4.2.Retail Pharmacy |
| 12.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.5.1.China |
| 12.5.2.India |
| 12.5.3.Australia and New Zealand (ANZ) |
| 12.5.4.Japan |
| 12.5.5.Rest of APAC |
| 13.Middle East and Africa (MEA) Cholinergic Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Powder |
| 13.1.2.Tablet |
| 13.1.3.Capsule |
| 13.2. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Muscarinic Agonists |
| 13.2.2.Nicotinic Agonists |
| 13.2.3.Acetylcholinesterase Inhibitors |
| 13.3. Induction Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Alzheimer's Disease |
| 13.3.2.Myasthenia Gravis |
| 13.3.3.Glaucoma |
| 13.3.4.Overactive Bladder |
| 13.3.5.Schizophrenia |
| 13.4. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Hospital Pharmacy |
| 13.4.2.Retail Pharmacy |
| 13.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.5.1.GCC Countries |
| 13.5.2.South Africa |
| 13.5.3.Rest of MEA |
| 14.Latin America Cholinergic Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 14.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.1.1.Powder |
| 14.1.2.Tablet |
| 14.1.3.Capsule |
| 14.2. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.2.1.Muscarinic Agonists |
| 14.2.2.Nicotinic Agonists |
| 14.2.3.Acetylcholinesterase Inhibitors |
| 14.3. Induction Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.3.1.Alzheimer's Disease |
| 14.3.2.Myasthenia Gravis |
| 14.3.3.Glaucoma |
| 14.3.4.Overactive Bladder |
| 14.3.5.Schizophrenia |
| 14.4. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.4.1.Hospital Pharmacy |
| 14.4.2.Retail Pharmacy |
| 14.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.5.1.Brazil |
| 14.5.2.Mexico |
| 14.5.3.Rest of LA |
| 15. Competition Landscape |
| 15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 15.2.1.GlaxoSmithKline plc |
| 15.2.2.Gilead Sciences Inc. |
| 15.2.3.Boehringer Ingelheim GmbH |
| 15.2.4.Daiichi Sankyo Company Limited |
| 15.2.5.UCB S.A. |
| 15.2.6.Sun Pharmaceutical Industries Ltd. |
| 15.2.7.Eisai Pharmaceutical Co. Ltd. |
| 15.2.8.Aurobindo Pharma Limited |
| 15.2.9.Ono Pharmaceutical Co. Ltd. |
| 15.2.10.Hikma Pharmaceuticals plc |
| 15.2.11.Lupin Limited |
| 15.2.12.H Lundbeck A/S |
| 15.2.13.Alvogen Inc. |
| 15.2.14.Mylan N.V. |
| 15.2.15.Nicox S.A |
| 15.2.16.Allergan India Private Limited |
| 16. Research Methodology |
| 17. Appendix and Abbreviations |
- GlaxoSmithKline plc
- Gilead Sciences Inc.
- Boehringer Ingelheim GmbH
- Daiichi Sankyo Company Limited
- UCB S.A.
- Sun Pharmaceutical Industries Ltd.
- Eisai Pharmaceutical Co. Ltd.
- Aurobindo Pharma Limited
- Ono Pharmaceutical Co. Ltd.
- Hikma Pharmaceuticals plc
- Lupin Limited
- H Lundbeck A/S
- Alvogen Inc.
- Mylan N.V.
- Nicox S.A
- Allergan India Private Limited